skip to Main Content

Dr. O’Reilly Discusses Biomarker Research in Pancreatic Cancer

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses biomarker research in pancreatic cancer.

There are many mutations that are characteristic of pancreatic cancer, such as KRAS, p53, CDKN2A, and SMAD4. However, those mutations are not yet targetable as there are no drugs that can effectively alter the outcomes of those patients. However, in KRAS, there are some therapies that might have impact, but further research is needed. Watch the video . . .


Back To Top